CN104902914B - 高纯度和优异产量的正确折叠的依那西普 - Google Patents

高纯度和优异产量的正确折叠的依那西普 Download PDF

Info

Publication number
CN104902914B
CN104902914B CN201380058650.5A CN201380058650A CN104902914B CN 104902914 B CN104902914 B CN 104902914B CN 201380058650 A CN201380058650 A CN 201380058650A CN 104902914 B CN104902914 B CN 104902914B
Authority
CN
China
Prior art keywords
etanercept
protein
resin
mixed mode
separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380058650.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104902914A (zh
Inventor
荒川力
道格拉斯·法勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104902914(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Priority to CN201811633164.2A priority Critical patent/CN110051823A/zh
Publication of CN104902914A publication Critical patent/CN104902914A/zh
Application granted granted Critical
Publication of CN104902914B publication Critical patent/CN104902914B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201380058650.5A 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普 Expired - Fee Related CN104902914B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811633164.2A CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
US61/699,552 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811633164.2A Division CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Publications (2)

Publication Number Publication Date
CN104902914A CN104902914A (zh) 2015-09-09
CN104902914B true CN104902914B (zh) 2019-01-01

Family

ID=50233493

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811633164.2A Pending CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普
CN201380058650.5A Expired - Fee Related CN104902914B (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811633164.2A Pending CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Country Status (33)

Country Link
US (6) US20140072560A1 (enExample)
EP (1) EP2895188B1 (enExample)
JP (3) JP2015533797A (enExample)
KR (2) KR102133699B1 (enExample)
CN (2) CN110051823A (enExample)
AR (1) AR092532A1 (enExample)
AU (2) AU2013315750B9 (enExample)
BR (1) BR112015005161A2 (enExample)
CA (1) CA2882551A1 (enExample)
CL (1) CL2015000572A1 (enExample)
CO (1) CO7400876A2 (enExample)
CY (1) CY1120062T1 (enExample)
DK (1) DK2895188T3 (enExample)
DO (1) DOP2015000055A (enExample)
EA (1) EA031324B1 (enExample)
EC (1) ECSP15014138A (enExample)
ES (1) ES2657377T3 (enExample)
HR (1) HRP20180182T1 (enExample)
HU (1) HUE036524T2 (enExample)
IL (2) IL237311B (enExample)
IN (1) IN2015KN00452A (enExample)
LT (1) LT2895188T (enExample)
MX (2) MX360044B (enExample)
NO (1) NO2972131T3 (enExample)
PE (2) PE20200607A1 (enExample)
PL (1) PL2895188T3 (enExample)
PT (1) PT2895188T (enExample)
RS (1) RS57013B1 (enExample)
SG (1) SG11201501460RA (enExample)
SI (1) SI2895188T1 (enExample)
SM (1) SMT201800163T1 (enExample)
TW (2) TWI716649B (enExample)
WO (1) WO2014043103A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
KR20140079491A (ko) 2011-10-18 2014-06-26 코히러스 바이오사이언시즈, 인코포레이티드 당과 폴리올과의 배합물로 안정화된 에타너셉트 제형
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
SG11201501460RA (en) * 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
ES2733298T3 (es) * 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
AU2015372801B2 (en) * 2014-12-31 2018-12-20 Lg Chem, Ltd. Method for preparing tnfr-fc fusion protein containing target content of impurities
WO2016149139A1 (en) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
RU2018121653A (ru) * 2015-11-18 2019-12-19 Мерк Патент Гмбх Улучшенное разделение белков при ионообменной хроматографии
US20180346510A1 (en) * 2015-11-18 2018-12-06 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
MX2018015173A (es) * 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
KR102446838B1 (ko) * 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3057286A1 (en) * 2017-03-24 2018-09-27 Council Of Scientific And Industrial Research A process for the purification of recombinant antibody fragments
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CA3182368A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
EP4308148A4 (en) * 2021-03-16 2025-01-29 Kashiv Biosciences, LLC NOVEL FORMULATION OF A FUSION PROTEIN
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CA3235508A1 (en) * 2021-10-19 2023-05-11 Soon Jae Park Method for purifying fusion protein having igg fc domain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239177A (zh) * 2008-02-29 2011-11-09 比奥根艾迪克Ma公司 纯化的免疫球蛋白融合蛋白及其纯化方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2399436A1 (en) 2000-02-10 2001-08-16 Loran Marie Killar Method of treating or inhibiting cellular injury or cell death
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
DE60236025D1 (de) * 2002-08-22 2010-05-27 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l-arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
BRPI0407649A (pt) 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
KR20070008501A (ko) 2003-08-01 2007-01-17 암젠 인코퍼레이티드 결정성 종양 괴사 인자 수용체 2 폴리펩티드
OA13315A (en) 2003-10-14 2007-04-13 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
EP1718386A1 (en) * 2004-02-27 2006-11-08 GE Healthcare Bio-Sciences AB A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
PE20071063A1 (es) 2005-12-20 2007-10-24 Bristol Myers Squibb Co Formulaciones de proteinas estables
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
ES2827180T3 (es) 2006-10-06 2021-05-20 Amgen Inc Formulaciones de anticuerpos estables
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
TR201820837T4 (tr) 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumab antikor formülasyonları.
RU2473360C2 (ru) 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SG177577A1 (en) 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
ES2793348T5 (en) 2009-08-11 2025-04-11 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
PL2563904T3 (pl) 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
CA2807895A1 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10995130B2 (en) 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
KR20230114317A (ko) 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
CA2840951A1 (en) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Methods for purifying fc-fusion protein
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
KR20140079491A (ko) * 2011-10-18 2014-06-26 코히러스 바이오사이언시즈, 인코포레이티드 당과 폴리올과의 배합물로 안정화된 에타너셉트 제형
PE20150762A1 (es) * 2012-07-09 2015-06-20 Coherus Biosciences Inc Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
SG11201501460RA (en) * 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
EP3879334B1 (en) * 2014-07-31 2023-11-29 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239177A (zh) * 2008-02-29 2011-11-09 比奥根艾迪克Ma公司 纯化的免疫球蛋白融合蛋白及其纯化方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法

Also Published As

Publication number Publication date
US20180037642A1 (en) 2018-02-08
PE20150996A1 (es) 2015-08-01
US11001627B2 (en) 2021-05-11
US10954293B2 (en) 2021-03-23
JP6913066B2 (ja) 2021-08-04
CO7400876A2 (es) 2015-09-30
US20190300600A1 (en) 2019-10-03
DK2895188T3 (en) 2018-02-26
HRP20180182T1 (hr) 2018-04-20
KR20150056601A (ko) 2015-05-26
DOP2015000055A (es) 2015-04-30
CN110051823A (zh) 2019-07-26
RS57013B1 (sr) 2018-05-31
US20190330325A1 (en) 2019-10-31
HUE036524T2 (hu) 2018-07-30
EA201590542A1 (ru) 2015-07-30
CA2882551A1 (en) 2014-03-20
AU2013315750B2 (en) 2018-07-12
PT2895188T (pt) 2018-02-08
EP2895188A1 (en) 2015-07-22
AU2013315750A1 (en) 2015-03-05
PL2895188T3 (pl) 2018-06-29
AU2018247244A1 (en) 2018-11-01
TWI716649B (zh) 2021-01-21
US10954295B2 (en) 2021-03-23
CN104902914A (zh) 2015-09-09
JP2015533797A (ja) 2015-11-26
US20190300601A1 (en) 2019-10-03
EP2895188B1 (en) 2017-11-15
US20190300602A1 (en) 2019-10-03
CL2015000572A1 (es) 2016-02-05
EA031324B1 (ru) 2018-12-28
CY1120062T1 (el) 2018-12-12
KR20200085937A (ko) 2020-07-15
IL237311A0 (en) 2015-04-30
LT2895188T (lt) 2018-04-10
SI2895188T1 (en) 2018-05-31
SMT201800163T1 (it) 2018-05-02
ECSP15014138A (es) 2016-01-29
IL267452B (en) 2021-05-31
US10947306B2 (en) 2021-03-16
TWI609877B (zh) 2018-01-01
US10954294B2 (en) 2021-03-23
MX2015003090A (es) 2015-07-14
SG11201501460RA (en) 2015-04-29
MX2018012749A (es) 2020-11-12
ES2657377T3 (es) 2018-03-05
IN2015KN00452A (enExample) 2015-07-17
AR092532A1 (es) 2015-04-22
TW201803593A (zh) 2018-02-01
TW201425331A (zh) 2014-07-01
PE20200607A1 (es) 2020-03-10
IL237311B (en) 2019-07-31
US20140072560A1 (en) 2014-03-13
KR102133699B1 (ko) 2020-07-14
JP2019038817A (ja) 2019-03-14
IL267452A (en) 2019-08-29
BR112015005161A2 (pt) 2017-07-04
AU2013315750B9 (en) 2018-11-15
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (enExample) 2018-04-21
MX360044B (es) 2018-10-19
WO2014043103A1 (en) 2014-03-20
JP2021100929A (ja) 2021-07-08
EP2895188A4 (en) 2016-05-25
AU2018247244B2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CN104902914B (zh) 高纯度和优异产量的正确折叠的依那西普
RU2736339C1 (ru) Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
CN103998061A (zh) 使用木糖醇稳定的依那西普制剂
TWI691512B (zh) Ｆｃ融合高親和性ＩｇＥ受體α鏈
TW201443234A (zh) 重組酵母菌轉形株及使用該轉形株製備免疫球蛋白ｆｃ片段之方法
HK40009767A (en) Correctly folded etanercept in high purity and excellent yield

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190101

CF01 Termination of patent right due to non-payment of annual fee